



**CSL Limited**  
ABN: 99 051 588 348  
655 Elizabeth Street  
Melbourne  
Victoria 3000 Australia  
T +613 9389 1911  
F +613 9389 1434  
[CSL.com](http://CSL.com)

# ASX Announcement

For immediate release

3 April 2025

## CSL RESPONDS TO PROPOSED U.S. TARIFFS

Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY)

CSL notes the announcement by the United States Administration on 2 April 2025 that it intends to impose reciprocal tariffs on imports from all countries.

At this stage pharmaceutical products are not subject to the reciprocal tariffs.

CSL is continuing to assess the broader impact of the tariffs and will monitor further announcements by the U.S. Government.

We look forward to working with U.S. administration to ensure American patients retain access to our lifesaving medicines.

Authorised for lodgement by:

**Fiona Mead**  
Company Secretary

---

**For further information, please contact:**

**Investors:**

**Chris Cooper**  
Head, Investor Relations  
CSL Limited  
P: +61 455 022 740  
E: [chris.cooper@csl.com.au](mailto:chris.cooper@csl.com.au)

**Media:**

**Brett Foley**  
Communications  
CSL Limited  
P: +61 461 464 708  
E: [brett.foley@csl.com.au](mailto:brett.foley@csl.com.au)